Indeed, TNBC is characterized by the absence of estrogen and progesterone receptors (ER/PR) and absence of human epidermal growth factor receptor 2 (HER2) overexpression, making it unresponsive to the conventional therapies used for the other BC subtypes. This evidence concerns the gene ERBB2 and breast cancer.